Korean Journal of Radiology,
Год журнала:
2019,
Номер
20(7), С. 1042 - 1042
Опубликована: Янв. 1, 2019
Hepatocellular
carcinoma
(HCC)
is
the
fifth
most
common
cancer
globally
and
fourth
in
men
Korea,
where
prevalence
of
chronic
hepatitis
B
infection
high
middle-aged
elderly
patients.
These
practice
guidelines
will
provide
useful
constructive
advice
for
clinical
management
patients
with
HCC.
A
total
44
experts
hepatology,
oncology,
surgery,
radiology,
radiation
oncology
Korean
Liver
Cancer
Association-National
Center
Korea
Practice
Guideline
Revision
Committee
revised
2014
developed
new
recommendations
that
integrate
up-to-date
research
findings
expert
opinions.
BackgroundA
single,
high
priming
dose
of
tremelimumab
(anti-cytotoxic
T
lymphocyte–associated
antigen
4)
plus
durvalumab
(anti–programmed
cell
death
ligand-1),
an
infusion
regimen
termed
STRIDE
(Single
Tremelimumab
Regular
Interval
Durvalumab),
showed
encouraging
clinical
activity
and
safety
in
a
phase
2
trial
unresectable
hepatocellular
carcinoma.MethodsIn
this
global,
open-label,
3
trial,
the
majority
patients
we
enrolled
with
carcinoma
no
previous
systemic
treatment
were
randomly
assigned
to
receive
one
three
regimens:
(300
mg,
dose)
(1500
mg
every
4
weeks;
STRIDE),
weeks),
or
sorafenib
(400
twice
daily).
The
primary
objective
was
overall
survival
for
versus
sorafenib.
Noninferiority
secondary
objective.ResultsIn
total,
1171
(n=393),
(n=389),
(n=389).
median
16.43
months
(95%
confidence
interval
[CI],
14.16
19.58)
STRIDE,
16.56
CI,
14.06
19.12)
durvalumab,
13.77
12.25
16.13)
Overall
at
36
30.7%,
24.7%,
20.2%,
respectively.
hazard
ratio
0.78
(96.02%
0.65
0.93;
P=0.0035).
monotherapy
noninferior
(hazard
ratio,
0.86;
95.67%
0.73
1.03;
noninferiority
margin,
1.08).
Median
progression-free
not
significantly
different
among
all
groups.
Grade
3/4
treatment-emergent
adverse
events
occurred
50.5%
37.1%
52.4%
sorafenib.ConclusionsSTRIDE
improved
Durvalumab
carcinoma.
(Funded
by
AstraZeneca;
ClinicalTrials.gov
number,
NCT03298451.)
Journal of Clinical Oncology,
Год журнала:
2018,
Номер
36(19), С. 1913 - 1921
Опубликована: Март 2, 2018
Purpose
Selective
internal
radiation
therapy
or
radioembolization
(RE)
shows
efficacy
in
unresectable
hepatocellular
carcinoma
(HCC)
limited
to
the
liver.
This
study
compared
safety
and
of
RE
sorafenib
patients
with
locally
advanced
HCC.
Patients
Methods
SIRveNIB
(selective
v
sorafenib),
an
open-label,
investigator-initiated,
phase
III
trial,
yttrium-90
(
90
Y)
resin
microspheres
800
mg/d
HCC
a
two-tailed
designed
for
superiority/detriment.
were
randomly
assigned
1:1
stratified
by
center
presence
portal
vein
thrombosis.
Primary
end
point
was
overall
survival
(OS).
Efficacy
analyses
performed
intention-to-treat
population
treated
population.
Results
A
total
360
(RE,
182;
sorafenib,
178)
from
11
countries
Asia-Pacific
region.
In
groups,
28.6%
9.0%,
respectively,
failed
receive
without
significant
cross-over
either
group.
Median
OS
8.8
10.0
months
respectively
(hazard
ratio,
1.1;
95%
CI,
0.9
1.4;
P
=
.36).
1,468
treatment-emergent
adverse
events
(AEs)
reported
437;
1,031).
Significantly
fewer
than
group
had
grade
≥
3
AEs
(36
130
[27.7%])
82
162
[50.6%];
<
.001).
The
most
common
ascites
(five
[3.8%]
four
[2.5%]
patients),
abdominal
pain
(three
[2.3%]
two
[1.2%]
anemia
(zero
hepatitis
(two
[1.5%]
zero
[0%]
patients).
Fewer
(27
[20.8%])
(57
[35.2%])
serious
AEs.
Conclusion
HCC,
did
not
differ
significantly
between
sorafenib.
improved
toxicity
profile
may
inform
treatment
choice
selected
patients.
Signal Transduction and Targeted Therapy,
Год журнала:
2020,
Номер
5(1)
Опубликована: Авг. 11, 2020
Abstract
The
last
3
years
have
seen
the
emergence
of
promising
targeted
therapies
for
treatment
hepatocellular
carcinoma
(HCC).
Sorafenib
has
been
mainstay
a
decade
and
newer
modalities
were
ineffective
did
not
confer
any
increased
therapeutic
benefit
until
introduction
lenvatinib
which
was
approved
based
on
its
non-inferiority
to
sorafenib.
subsequent
success
regorafenib
in
HCC
patients
who
progress
sorafenib
heralded
new
era
second-line
quickly
followed
by
ramucirumab,
cabozantinib,
most
influential,
immune
checkpoint
inhibitors
(ICIs).
Over
same
period
combination
therapies,
including
anti-angiogenesis
agents
with
ICIs,
dual
ICIs
conjunction
surgery
or
other
loco-regional
extensively
investigated
shown
promise
provided
basis
exciting
clinical
trials.
Work
continues
develop
additional
novel
could
potentially
augment
presently
available
options
understand
underlying
mechanisms
responsible
drug
resistance,
goal
improving
survival
HCC.
